STING1 and neoplasm: We do not anticipate that short-term PLGA-IMP treatment will interfere with cancer therapies as we have previously reported that treatment of mice with PLGA nanoparticles can modulate the anti-tumor immune response such that anti-tumor NK cell and CD8+ T cell responses are increased via the activation of the STING pathway31,32.